Inhibition of the NLRP3 inflammasome is a promising strategy for the development of new treatments for inflammatory diseases. MCC950 is a potent and specific small-molecule inhibitor of the NLRP3 pathway, but its molecular target is not defined. Here, we show that MCC950 directly interacts with the Walker B motif within the NLRP3 NACHT domain, thereby blocking ATP hydrolysis and inhibiting NLRP3 activation and inflammasome formation.
1
. Caspase-1 then cleaves the pro-inflammatory cytokines prointerleukin-1β (IL-1β) and pro-IL-18, mediating the secretion of their active cytokines. Caspase-1 also cleaves Gasdermin-d, triggering pyroptosis 2, 3 . NLRP3-driven inflammation is pathological in the development of many diseases including cryopyrin-associated periodic syndromes, Alzheimer's Disease, Parkinson's Disease, gout, atherosclerosis, non-alcoholic fatty liver disease, asthma and silicosis [4] [5] [6] . Inhibitors of NLRP3 are thus potential treatments for these conditions with unmet clinical needs.
We previously described MCC950 (CP-456,773, CRID3), a potent and specific small-molecule inhibitor of the NLRP3 inflammasome 7 . MCC950 has since been validated in vivo in numerous species and disease models [8] [9] [10] , and is a useful tool molecule for the field 11, 12 . It is important to identify the mechanism of action and molecular target of a small molecule to inform and de-risk drug development 13 . We reported that MCC950 did not suppress NLRP3 activity via effects on inflammasome priming, calcium signaling, potassium efflux or NLRP3-ASC interaction 7 . Other studies demonstrated that MCC950 inhibits potassium efflux-independent NLRP3 activation 14, 15 but does not block mitochondrial respiration or reactive oxygen species production 14 . NLRP3 activation requires interaction with NEK7 16 , and MCC950 is postulated to target NEK7 to block NLRP3 activation 3, 17 . Although the capacity of MCC950 to block NLRP3 signaling is well established, we sought to identify the molecular target of MCC950 and more precisely delineate its mechanism of action.
MCC950 specifically inhibits NLRP3 among inflammasomes 7, 18 , and blocks canonical, non-canonical and alternative NLRP3 activation 7, 14, 15 . We thus hypothesized that MCC950 directly inhibits NLRP3. We initially tested this using a drug affinity responsive target stability (DARTS) approach 19 , using mouse bone marrowderived macrophages (BMMs) and the broad specificity protease mix, pronase. The assay was optimized ( Supplementary Fig. 1 ) to induce degradation of NLRP3, as indicated by immunoblot detection of numerous pronase-induced NLRP3 fragments. Increasing doses of MCC950 (0.1-10 μM) protected NLRP3 from pronasemediated degradation, as evident from the changes in digestion pattern detected using antibodies against the NACHT or PYD domains (Fig. 1a) . The effect of MCC950 was specific to NLRP3; MCC950 did not block the degradation of NEK7 or glyceraldehyde 3-phosphate dehydrogenase (GAPDH) at the optimized pronase concentration (Fig. 1a) or a lower pronase concentration ( Supplementary  Figs. 1 and 2a ). MCC950 similarly limited NLRP3 protein degradation in primary human monocyte-derived macrophages ( Supplementary Fig. 2b ), and by an alternative protease, thermolysin ( Supplementary Fig. 2c ). We next examined whether NLRP3 activation status affected MCC950-dependent protease protection. We performed DARTS assays using lipopolysaccharide (LPS)-primed BMM stimulated with the NLRP3 activator, nigericin, and then treated with MCC950 and compared this to MCC950 exposure to unstimulated or single-stimulated controls in which NLRP3 is not activated.
) BMM were used to prevent inflammasome-mediated cell death. MCC950 protected NLRP3 from degradation in all conditions ( Supplementary Fig. 2d ). This suggests that MCC950 directly interacts with NLRP3 in both its inactive and active conformations.
To verify that MCC950 interacts with NLRP3, we used a photoaffinity labeling strategy. On the basis of the structure of MCC950, we synthesized a benzophenone and alkyne-containing photoaffinity probe (PAP) (1) that inhibits NLRP3 activation ( Supplementary  Fig. 3 ) and covalently cross-links to its molecular target when activated by ultraviolet light. Recombinant human NLRP3 without the leucine rich repeat (LRR) domain (NLRP3∆LRR, Fig. 1b and Supplementary Fig. 4 ) and BMM lysates (Fig. 1c) were treated with the PAP, in the presence or absence of MCC950 to compete for binding. Following ultraviolet exposure, the PAP was linked to biotin-azide via Cu(I)-catalyzed click chemistry and purified using streptavidin magnetic particles. The biotinylated PAP indeed pulled down recombinant NLRP3∆LRR (Fig. 1b) and NLRP3 from BMM lysates (Fig. 1c) , and these interactions were suppressed by MCC950 competition (Fig. 1b,c) , confirming that MCC950 directly interacts with NLRP3.
To identify the NLRP3 domain that binds to MCC950, we expressed full-length NLRP3 versus truncation mutants (Fig. 2a) in HEK293T cells and performed DARTS assays (Fig. 2b-d) . MCC950 protected full-length and ∆LRR NLRP3 (Fig. 2b,c, see arrows) , but . DARTS assay was performed with pronase (500 ng μg −1 of protein), and lysates were analyzed by immunoblot using antibodies for NLRP3 PYD (cryo-2), NLRP3 NACHT (D4D8T), NEK7 and GAPDH. b,c, Recombinant human NLRP3∆LRR (b) or LPS-primed BMM lysates (c) were treated with 5 μM MCC950 or vehicle control. Samples were then treated with 5 μM photoaffinity probe and exposed to 20 W 365 nm ultraviolet light (UV) for 90 min. Biotinylation reagents were added and incubated at room temperature for 60 min, or biotin was omitted as a control. Total protein was precipitated, and samples were resuspended and incubated with streptavidin paramagnetic particles. Interacting proteins were analyzed by immunoblot. Data are representative of N = 5 (a) or N = 2 (b,c) independent experiments. Uncropped western blots are presented in Supplementary Fig. 9 . not the NLRP3 PYD domain (Fig. 2d ) from degradation, suggesting that MCC950 binds to the central NACHT domain. The NLRP12 NACHT is the most closely related to the NLRP3 NACHT within the NLR family 20 . A chimeric form of NLRP3 ('NACHT12'), in which the NACHT is swapped for that of NLRP12, was not protected by MCC950 in a DARTS assay ( Supplementary Fig. 5 ). This indicates that MCC950 specifically interacts with the NLRP3 NACHT domain.
We next sought to identify the MCC950-interaction site within the NACHT domain. The D4D8T antibody clone was raised against residues around Alanine 306 within the NLRP3 NACHT domain ( Supplementary Fig. 6a ). We used this antibody to immunoprecipitate NLRP3 in LPS-primed BMM (Fig. 3a) . MCC950 dose-dependently decreased the efficiency of NLRP3 immunoprecipitation, suggesting that MCC950 interacts with NLRP3 at a site close to the epitope of this antibody and thereby blocks antibody-NLRP3 interactions. MCC950 also suppressed D4D8T-mediated, but not anti-mCherry antibody-mediated, immunoprecipitation of mCherry-tagged NLRP3 ( Supplementary Fig. 6b ), indicating that the effect of MCC950 is specific for the D4D8T antibody. Immunoprecipitation assays were also performed with lysates from Asc −/− BMM under conditions where NLRP3 is active (LPS plus nigericin) or inactive (single-stimulated or untreated controls). MCC950 blocked D4D8T-mediated NLRP3 immunoprecipitation in all conditions (Fig. 3b) , validating previous observations from DARTS assays ( Supplementary Fig. 2d ) that MCC950 interacts with both active and inactive NLRP3.
Alanine 306 of mouse NLRP3 is located near the ATP binding (Walker A) and hydrolysis (Walker B) motifs ( Supplementary  Fig. 6a ). To define the D4D8T antibody epitope, we tested its ability to detect NLRP3 Walker A and Walker B motif mutants or the NACHT12 chimera ( Supplementary Fig. 6c ). The D4D8T antibody failed to recognize the NLRP12 NACHT, and poorly detected NLRP3 mutants in which the key Walker B motifs are substituted (Walker B single or A + B double mutants) while the NLRP3 Walker A single mutant was readily detected. As this suggested that the D4D8T antibody binds to NLRP3 at the Walker B motif, we next used DARTS assays to determine whether Walker B mutation disrupts MCC950 binding. Immunoblotting revealed that while MCC950 prevented the degradation of wild-type NLRP3 and the inactive Walker A mutant ( Fig. 3c and Supplementary Fig. 6d , see arrows), MCC950 did not protect the Walker B or Walker A + B mutants from protease degradation ( Fig. 3d and Supplementary Fig. 6e ). These data indicate that MCC950 interacts with NLRP3 proximal to the Walker B motif.
The kinetics of MCC950 activity, and whether it is a covalent NLRP3 inhibitor, is unknown. In LPS-primed BMM, MCC950 potently inhibits nigericin-induced IL-1β release and cell death ( Fig. 3e and Supplementary Fig. 7 ). When MCC950 was washed out before nigericin treatment, however, its potency markedly decreased ( Fig. 3e and Supplementary Fig. 7) , with a shift in halfmaximum inhibitory concentration (IC 50 ) from approximately 24 nM to 1.7 μM. To further establish MCC950-NLRP3 interaction kinetics, we performed surface plasmon resonance (SPR) with immobilized recombinant NLRP3∆LRR. MCC950 binds to NLRP3∆LRR with high affinity (K D = 224 nM) and a rapid off-rate
) ( Fig. 3f and Supplementary Table 1), supporting our observation that MCC950 can be readily washed out in cell-based assays (Fig. 3e) . Thus, MCC950 is a reversible NLRP3 inhibitor.
We next sought to determine the impact of MCC950 interaction on NLRP3 molecular function. Given that MCC950 binds proximal to the Walker B motif that mediates ATP hydrolysis (Fig. 3a-d) , and ATP hydrolysis is required for NLRP3 inflammasome assembly and function 21 , we hypothesized that MCC950 may inhibit NLRP3 by suppressing its ATPase activity. ATP indeed binds to NLRP3∆LRR (K D = 2.05 μM), with an off-rate (k d = 24.15 s ) consistent with ATP hydrolysis by NLRP3 (Fig. 3f and Supplementary Table 1) . When NLRP3∆LRR was exposed to both MCC950 and ATP, these two molecules did not compete for NLRP3∆LRR binding (Fig. 3f) , but remarkably, led to high-affinity, stable interaction (K D = 10.6 nM,
; Fig. 3f and Supplementary Table 1 ). In contrast, ADP binds poorly to NLRP3∆LRR, and its combination with MCC950 does not induce a high-affinity, stable interaction ( Fig. 3g and Supplementary Table 1 ). The NLRP3∆LRR Walker B mutant did not interact with MCC950 (Fig. 3h, Supplementary Fig. 8a and Supplementary Table 1), but did bind ATP, as is anticipated from the intact NLRP3 Walker A site. Confirming earlier observations, recombinant NEK7 did not bind MCC950 ( Supplementary Fig. 8b ,c and Supplementary Table 1 ), but did interact with ATP, as expected from NEK7 kinase function. Altogether, these data indicate that MCC950 binds proximal to the NLRP3 Walker B motif and prevents NLRP3 from hydrolyzing ATP to ADP.
In summary, we reveal the molecular mechanism of action of MCC950. MCC950 specifically binds to both active and inactive NLRP3, in a high-affinity non-covalent interaction at or adjacent to the Walker B motif, thereby blocking the ability of NLRP3 to hydrolyze ATP for NLRP3 inflammasome function. Our data confirm the critical role of ATP binding and hydrolysis to NLRP3 function 21 , consistent with the known ATP-dependent oligomerization mechanisms of NLRC4 (ref. 22, 23 ) and other AAA + ATPases
24
. The accompanying study by Tapia-Abellán et al. 25 reports that NLRP3 undergoes structural rearrangements to open out during activation, and that MCC950 counters this via interaction with the NLRP3 Walker B site, driving NLRP3 toward a closed and inactive conformation. These complementary studies together show that MCC950 binds to NLRP3 and prevents it from assuming or retaining its active open conformation, thereby blocking NLRP3 oligomerization and inflammasome function. They further suggest that ATP hydrolysis is required not only for NLRP3 to assume its open conformation during activation, but also for maintaining this active conformer. Our elucidation of MCC950 mechanism of action paves the way for further rational development of small-molecule inhibitors to treat NLRP3-driven inflammatory diseases.
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Methods
MCC950 synthesis and formulation. MCC950 sodium salt was synthesized as previously described 7 . MCC950 sodium salt stock solutions were prepared in H 2 O.
Mouse and human primary macrophage cell culture. All experimental protocols involving mice were approved by the University of Queensland Animal Ethics Committee. Studies using primary human cells were approved by the University of Queensland Human Medical Research Ethics Committee. We have complied with all relevant ethical regulations. C57BL/6 and Asc −/− (ref. 26 ) mice were housed in specific pathogen-free facilities at the University of Queensland. The Australian Red Cross Blood Service receives blood donations from informed and consenting healthy adult donors, and provided buffy coats from anonymous donors for this research study. Peripheral blood mononuclear cells were isolated from buffy coats by density centrifugation using Ficoll-Paque Plus (GE Healthcare). CD14 + monocytes were then isolated using magnetic-activated cell sorting (Miltenyi Biotech), according to the manufacturer's instructions. Human and murine macrophages were differentiated from human CD14 + monocytes and murine bone marrow as previously described, and were used for experiments on day 7 of differentation 27 . Mouse BMMs and human monocyte-derived macrophages (HMDMs) were cultured in media consisting of RPMI 1640 medium (Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM GlutaMAX (Life Technologies), 50 U per ml penicillin-streptomycin (Life Technologies) and 150 ng ml −1 recombinant human macrophage colonystimulating factor (CSF-1 (endotoxin free, expressed and purified by the University of Queensland Protein Expression Facility)).
HEK293T cell culture and transfection. HEK293T cells were cultured in DMEM containing high glucose, pyruvate (Life Technologies) and supplemented with 10% FCS and 50 U per ml penicillin-streptomycin. HEK293T cells (3 × 10 5 per ml) were transfected in 10 cm dishes via the calcium phosphate method with 5 μg of plasmid DNA. The mammalian expression vector, pEF6, was used for all plasmids and contained mouse NLRP3 with a C terminal mCherry tag: full-length wild-type NLRP3, NLRP3ΔLRR, NLRP3 PYD, NLRP3 Walker A mutant (G227A, K228A, T229A), NLRP3 Walker B mutant (D298A, D301A, E302A), NLRP3 Walker A and B double mutant (G227A, K228A, T229A, D298A, D301A, E302A) and NLRP3-NLRP12 NACHT domain chimera.
DARTS assays.
Assays were adapted from published protocols 19, 28, 29 . Differentiated BMM and HMDM were plated at a density of 5 × 10 5 cells per ml in 10 cm dishes in full media. The next day media were removed and replaced with Opti-MEM supplemented with CSF-1. Cells were primed with ultrapure Escherichia coli K12 LPS (100 ng ml ) for 4-6 h, and MCC950 (0.1-10 μM) was added for the final hour. In some experiments, cells were primed with ultrapure E. coli K12 LPS (100 ng ml HEK293T cells were gathered 24 h after transfection. Media were removed and cells were washed in PBS (±MCC950), cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM ATP, 2 mM EDTA, 0.5% Igepal CA-630) containing protease inhibitors (complete mini protease inhibitor cocktail; Roche), benzonase and MCC950 as indicated. Lysates were disrupted by passage through a 27-gauge needle and cleared by centrifugation at 14,000g for 10 min at 4 °C. Protein concentration was determined using a Pierce BCA Protein Assay Kit (Life Technologies), and a minimum of 20 μg of protein lysate was used per reaction. Pronase and thermolysin (10 mg ml −1 , (Sigma-Aldrich) were added at the indicated protease to protein ratio, between 50-500 ng pronase or 0.05-5 μg Thermolysin per μg of protein in the sample, for the indicated time (7.5-30 min) at room temperature. The reaction was stopped by addition of 20× protease inhibitor cocktail and incubated on ice for 10 min. Protein samples were analyzed by immunoblotting.
Photoaffinity labeling and affinity purification of probe-modified proteins.
The photoaffinity labeling and purification methodology was adapted from Xu et al. 30 and MacKinnon and Taunton 31 . BMM were plated at a density of 5 × 10 5 cells per ml in 10 cm dishes in full media. The next day cells were primed with ultrapure E. coli K12 LPS (50 ng ml −1 ) for 4-6 h. Media were removed and cells were washed in PBS and then lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM ATP, 0.5% Igepal CA-630) containing protease inhibitors and benzonase. Lysates were disrupted by passage through a 27-gauge needle and cleared by centrifugation at 14,000g for 10 min at 4 °C. Clarified lysates (1 ml) were added to a 24-well tissue culture plate. Recombinant NLRP3ΔLRR was diluted in lysis buffer and 150 μl was added to a 48-well tissue culture plate. Samples were treated with 5 μM PAP plus 5 μM MCC950 or 5 μM PAP plus vehicle control. Photo-cross-linking was performed for 90 min, mixing after 45 min, using a custom-made light box equipped with a UVA fluorescent tube (Sylvania, 20 W, 365 nm). Sample plates were placed on ice and within 2 cm of the fluorescent tube. Biotinylation was performed by adding the following reagents, with final concentrations indicated: biotin-PEG3-azide (biotin-N 3 , 100 μM), tris[ (1-benzyl-1H-1,2,3-triazol-4-yl) methyl]amine (TBTA; 100 μM), tris(2-carboxyethyl)phosphine hydrochloride (TCEP, 1 mM) and CuSO 4 5H 2 O (1 mM), except in the case of the control where biotin-N 3 was omitted. Following reagent addition, plates were mixed at room temperature for 1 h. Protein samples were then precipitated with acetone and frozen at −20 °C overnight. Precipitated protein was pelleted by centrifugation at 17,000g for 15 min at 4 °C. Cold acetone precipitation was repeated twice and protein pellets were then solubilized in 1% SDS in PBS and diluted in affinity purification buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 1% Triton X-100). Streptavidin MagneSphere paramagnetic particles (Promega) were blocked with 1% BSA PBS and washed with affinity purification buffer. The protein samples were incubated with streptavidin paramagnetic particles with gentle rotation for 3 h at 4 °C. Particles were washed twice in affinity purification buffer and four times in wash buffer (50 mM HEPES pH 7.4, 500 mM NaCl, 1% Triton X-100). Bound proteins from BMM lysates were eluted by the addition of elution buffer (2 mM D-biotin, 1% v/v Triton X-100, PBS) and incubation at 95 °C for 5 min. Bound protein from the recombinant NLRP3ΔLRR experiments were eluted by boiling particles for 5 min in affinity purification buffer containing NuPAGE LDS sample buffer (Thermo Fisher Scientific) and 10 mM dithiothreitol (DTT). Eluted proteins were analyzed by immunoblot.
Immunoblotting. Protein samples were prepared with NuPAGE LDS sample buffer (Thermo Fisher Scientific) supplemented with 10 mM DTT. Samples were then resolved by SDS-PAGE using 4-20% Mini-PROTEAN TGX stain-free gels (Biorad) and transferred onto nitrocellulose membrane using the TransBlot Turbo transfer system (Biorad). Membranes were blocked in 5% (wt/vol) dried milk in TBS-T (10 mM Tris/HCl, pH 8, 150 mM NaCl and 0.05% (vol/vol) Tween-20) for 1 h at room temperature. Membranes were incubated with primary antibody diluted in 5% (wt/vol) dried milk in TBS-T and then with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody diluted in 5% (wt/vol) dried milk in TBS-T for 1 h. Membranes were developed using Clarity Western ECL substrate (Biorad). Membranes were then visualized using X-ray film (Fujifilm) developed using an X-OMAT 2000 processor (KODAK) or were visualized using a ChemiDoc MP Imaging System with Image Lab 6.0 (Biorad). Secondary antibodies on membranes were inactivated by incubation with 30% hydrogen peroxide before re-probe. Primary antibodies used were: NLRP3 clone Cryo-2 at 1:1,000 (AG-20B-0014, Adipogen), NLRP3 clone D4D8T at 1:1,000 (15101, Cell Signaling Technology), NEK7 clone EPR4900 at 1:5,000 (ab133514, Abcam), mCherry polyclonal at 1:5,000 (5993, Biovision) and GAPDH polyclonal at 1:5,000 (2275-PC, R&D Systems). Secondary HRP-conjugated antibodies used were anti-rabbit IgG and anti-mouse IgG both at 1:5,000 (7074, 7076, Cell Signaling Technology).
Immunoprecipitation assay. Differentiated BMMs were plated at a density of 5 × 10 5 cells per ml in 10 cm dishes in full media. The next day, media were removed and replaced with Opti-MEM supplemented with CSF-1. Cells were primed with ultrapure E. coli K12 LPS (100 ng ml −1 ) for 6 h, or were primed for 4 h and stimulated with 5 μM nigericin (Sigma-Aldrich) for 30 min where indicated. Media were removed and cells were washed in PBS containing MCC950 (0.01-10 μM) or vehicle control. Cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM ATP, 2 mM EDTA, 0.5% Igepal CA-630) containing protease inhibitors, benzonase and MCC950 (0.01-10 μM) or vehicle control. Lysates were disrupted by passage through a 27-gauge needle and cleared by centrifugation at 14,000g for 10 min at 4 °C. Clarified lysates were spiked with additional MCC950 (0.01-10 μM) and incubated with α-NLRP3 antibody (D4D8T) at 1:1,000 and Dynabeads Protein G (Life Technologies) with gentle rotation at 4 °C overnight. The beads were washed four times with lysis buffer containing MCC950 (0.01-10 μM) and immunoprecipitated samples and input (2%) were analyzed by immunoblot.
NLRP3 inflammasome and MCC950 washout assay. Differentiated BMM were plated at a density of 1 × 10 6 cells per ml in full media. The next day, media were removed and replaced with Opti-MEM (Life Technologies) supplemented with CSF-1. Cells were primed with ultrapure E. coli K12 LPS (100 ng ml ) for 4 h. Medium was removed and replaced with Opti-MEM containing MCC950 (0.001-10 μM). For washout cells only, after 30 min the medium was removed and replaced with Opti-MEM, cells were incubated for 1 min and medium was again removed and replaced with Opti-MEM. Cells were then stimulated with 5 μM nigericin or 1.25 mM ATP (Sigma-Aldrich) for 1 h. IL-1β in cell-free supernatants was analyzed by ELISA (eBioscience). Cellular cytotoxicity was quantified using the Cytox96 non-radioactive cytotoxicity assay (Promega) and displayed as a percentage of total cellular LDH (100% cell lysis control).
Recombinant NLRP3 protein expression. Human NLRP3ΔLRR (NCBI isoform e, NP_001230062.1, residues 1-649) was cloned in PGEX-6p-1 and expressed in BL21 competent E. coli as an N terminal glutathione S-transferase (GST)-fusion protein for 8 h at 18 °C using 200 μM isopropyl β-d-1-thiogalactopyranoside (Bioline). Bacteria were then sonicated and GST-NLRP3ΔLRR was isolated using MagneGST glutathione paramagnetic particles (Promega). GST was cleaved off by incubating the MagneGST particles with 3 C protease for 1 h at room temperature. NLRP3ΔLRR was concentrated using Amicon Ultra Centrifugal filter units (Merck) and stored at −80 °C. The Walker B mutant (D300A, D303A, E304A) was generated using a New England Biolabs Q5 site-directed mutagenesis kit.
Recombinant NEK7 protein expression. Human NEK7 was inserted via ligationindependent cloning into the His tag vector pMCSG7 (ref. 32 ) and expressed in BL21(DE3) competent E. coli as an N terminal His tag-fusion protein for 15 h at 20 °C using 1 mM isopropyl β-d-1-thiogalactopyranoside. Bacteria were collected, resuspended in lysis buffer (50 mM HEPES, pH 8.0, 300 mM NaCl, 30 mM imidazole, 1 mM DTT and 1 mM PMSF) and disrupted by sonication. His tag NEK7 was isolated by immobilized nickel affinity chromatography using a 5-ml HisTrap Fast Flow column (GE Healthcare). The protein was block eluted in 500 mM imidazole and further purified using a Superdex 200 SEC column (GE Healthcare). Peak fractions were combined and flash frozen in liquid nitrogen for storage at −80 °C. SPR analysis of recombinant proteins. SPR for affinity and competition analysis was carried out using a ForteBio Pioneer SPR system. NLRP3ΔLRR, NLRP3ΔLRR Walker B mutant or NEK7 were loaded onto flow cell 1 and 3 of a COOH5 chip and flow cell 2 was blank immobilized to enable reference subtraction in PBS. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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